查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853632

心血管吻合器市場按產品類型、機制、手術類型和最終用戶分類 - 全球預測 2025-2032 年

Cardiovascular Anastomosis Devices Market by Product Type, Mechanism, Procedure Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心血管吻合裝置市場規模將成長 45.5 億美元，複合年成長率為 11.00%。

關鍵市場統計數據
基準年 2024 19.7億美元
預計年份：2025年 21.9億美元
預測年份 2032 45.5億美元
複合年成長率 (%) 11.00%

對目前心血管吻合術的設備生態系統、臨床考量和營運重點進行清晰權威的闡述

心血管吻合裝置融合了外科技術、材料科學和系統級醫療服務。本文概述了目前用於建立和固定血管及心臟連接的各種手術工具，重點闡述了裝置外形規格、作用機制和臨床工作流程如何相互作用並影響手術結果。該領域正從手動縫合發展到機械化、能量輔助和混合式解決方案，旨在提高手術的可重複性、縮短手術時間並減少併發症。

本文介紹的各類器械中，臨床醫生和醫療機構在評估其性能時，不僅關注易用性，還日益重視耐用性、止血效果以及與微創和機器人手術的兼容性。新型聚合物、金屬和能量輸送系統的整合，在拓展外科醫生選擇的同時，也增加了採購、培訓和監管流程的複雜性。隨著相關人員接受新的方法，器械有效性、臨床操作舒適度和手術總成本之間的平衡將成為商業性討論的核心。

本導言為下一部分奠定了基調，其中包括對正在重塑臨床實踐的重大變革的分析、主導情景的關稅影響分析、闡明產品和臨床細分市場的細分洞察，以及旨在為實際策略提供資訊的區域和競爭情報。其目標是為決策者提供清晰的主題要點，以支持其製定短期戰術性選擇和中期戰略規劃。

微創趨勢、材料突破、器材互通性和不斷演變的採購模式如何重新定義外科吻合術

多項變革性變化正在再形成心血管吻合器材的設計、應用和商業化方式，其影響涵蓋臨床、生產和健保報銷等多個領域。首先，微創和機器人輔助手術的穩定發展推動了對能夠在有限空間內實現穩定、可重複吻合的器械的需求。這一趨勢加速了外形規格以及與機器人平台整合的迭代改進。因此，產品開發如今更加重視模組化介面和相容性標準，從而加快臨床應用並減輕訓練負擔。

其次，從可吸收組件的聚合物配方到止血夾的新型合金和塗層，材料創新正在延長器械的使用壽命並提高其生物相容性，同時使工程師能夠縮小器械體積並提高部署可靠性。同時，電熱和超音波等能量型技術也不斷改進，以減少出血、縮短手術時間，並在與臨床適應症適當匹配時提供可控的組織效應。

第三，隨著門診手術中心手術量增加和醫院追求基於價值的指標，採購動態也在不斷變化。最後，日益成長的監管和臨床證據要求促使企業投資於嚴謹的對照試驗和真實世界證據，以證明產品的安全性和有效性，以及下游經濟效益和工作流程最佳化。這些因素共同創造了一種市場環境，在這種環境中，技術差異化、臨床檢驗和分銷靈活性將決定醫療器材的市場主導。

對不斷變化的美國關稅動態將如何推動供應鏈重組、價格壓力以及增強本地製造業韌性的機會進行實際分析

主要市場政策變化導致的關稅徵收和提高，可能會對心血管吻合器材製造商和經銷商的供應鏈選擇、籌資策略和零件經濟效益產生重大影響。當進口關稅訂定或提高時，依賴跨境採購精密金屬零件、先進聚合物、電控系統和機器人子系統的公司必須重新評估供應商關係和庫存管理，以維持利潤率和供貨能力。

實際上，關稅往往會導致短期成本轉嫁給買家，並壓縮供應商的利潤空間，從而迫使製造商重新設計設備，減少對關稅敏感的投入，或認證本地製造商供應關鍵子組件。製造商可能會尋求建立區域生產基地或簽訂免收費用製造協議，以減輕定向關稅的影響。同時，更高的進口成本可能會加速高關稅風險零件的垂直整合，並促使製造商收購或與專業供應商建立合作關係，以確保供應的連續性並降低單位成本波動。

在臨床層面，採購團隊和醫院系統將透過收緊評估標準、增加競爭性競標以及在適當情況下優先考慮多功能或可重複使用的解決方案來應對關稅主導的價格波動。鑑於新的投入成本現實，報銷管理人員和價值委員會可能會要求更清晰的成本效益指標。對於推動創新的企業而言，關稅既是挑戰也是機會。雖然關稅可能會加劇短期內的商業性摩擦，但它們也會促進產品簡化、敏感供應鏈的本地化以及漸進式改進的開發，從而減少對進口原料和成品的依賴。因此，關稅情境應納入策略規劃，將其視為持續存在的供應鏈和定價風險，需要採購、監管事務和產品開發部門協調應對。

整合多維細分，結合產品類型、機制、流程和最終用戶參數，揭示精準的臨床和商業性目標區域。

了解產品和臨床細分市場需要採用多層次的細分方法，以確定最具創新和商業化潛力的目標。產品類型包括夾子、縫合器和縫合線。夾子用於快速血管控制，包括止血夾和血管夾。止血夾本身有金屬和聚合物兩種材質，需要在耐用性和影像相容性之間進行權衡。縫合器分為圓形和直線型，直線型縫合器又分為非加強型和加強型，以適應不同的組織厚度和防滲漏性能。縫合線分為自動縫合器和手動縫合器，自動縫合器又分為手持縫合器和機器人縫合器。

根據作用機制，止血方法可分為黏合劑、夾持系統、壓迫裝置、能量型止血方法和縫合器。黏合劑包括生物纖維蛋白膠和合成密封劑，每種密封劑的操作性和止血效果各不相同。壓迫裝置包括吻合環和扣帶，可以是永久性的、可生物吸收的或金屬材質的。能量型止血裝置利用電熱、雷射或超音波來封閉組織並控制出血，同時最大限度地減少熱損傷。

冠狀動脈繞道術（無論是否體外循環）都面臨一系列獨特的吻合挑戰，而頸動脈、股膕動脈和腎臟介入等周邊血管手術則需要針對血管尺寸、可及性和斑塊負荷進行最佳化的器械。瓣膜修復手術還增加了額外的解剖和動態限制，這些限制會影響器械的選擇和植入技術。門診手術中心、醫院和專科診所在設備佔地面積、消毒流程和人員訓練方面都有不同的要求。了解這些細分層面的相互關聯性，有助於企業根據每個不同的臨床和營運環境的實際情況，調整產品設計、臨床證據產生和商業化路徑。

區域臨床重點、法規環境和供應鏈佈局將如何影響美洲、歐洲、中東和非洲以及亞太地區的醫療器材採用情況

區域動態影響醫療器材的採納路徑、監管障礙和供應鏈設計，進而影響策略和執行。在美洲，臨床上高度重視微創冠狀動脈和周邊血管介入治療，這與成熟的醫保報銷系統和完善的醫院採購流程相輔相成。主要市場的醫療機構優先考慮那些手術時間更短、併發症率更低且能與現有手術平台整合的醫療器材。同時，區域製造商和委託製造在本地化供應和補貨方面發揮關鍵作用，使高容量醫療機構受益。

歐洲、中東和非洲地區（EMEA）是一個異質性區域，各國監管環境和強大的採購機構會在證據確鑿時加速產品推廣應用，但市場分散也要求制定量身定做的監管和報銷策略。一些歐洲市場對真實世界證據和成本效益資料要求很高，採購機構通常要求提供用於永久或半永久使用的醫療設備的長期安全性資訊。

亞太地區的特點是手術量快速成長、醫院基礎設施投資不斷擴大，以及既包括高階三級醫療中心也包括資源有限的醫療機構的雙重市場結構。本地原始設備製造商 (OEM) 和區域供應鏈日益成熟，跨國供應商為了滿足監管和成本要求，往往尋求合作夥伴關係和本地化生產。無論在哪個地區，能夠使其產品系列與當地手術模式、監管時間表和採購模式相匹配的公司，都將擁有最清晰的持續市場認可路徑。

對塑造設備領導地位的競爭定位、夥伴關係關係動態、供應商集中度和創新路徑進行了深刻剖析。

心血管吻合器材市場的競爭格局正由成熟的醫療設備製造商、專注於特定領域的中型創新企業以及數量不斷成長的科技型新興企業共同塑造。現有企業正利用其廣泛的商業網路、豐富的監管經驗和現有的臨床關係迅速擴大配銷通路，而規模較小的製造商則致力於開發顛覆性技術——例如先進的能量控制演算法、新型可吸收聚合物和緊湊型機器人縫合模組——以吸引早期採用的外科醫生和戰略收購方。

醫療器材製造商與機器人平台供應商之間的夥伴關係和共同開發契約日益加強，雙方都在尋求互通性和捆綁式臨床價值提案。材料科學家、臨床研究人員和系統工程師之間的跨學科合作催生了一系列漸進式創新，這些創新改進了操作性、縮小了器械體積並增強了止血效果。同時，監管趨勢強調臨床證據和上市後監測，提高了新參與企業的進入門檻，使得臨床試驗設計、註冊登記參與和正式的衛生經濟學分析成為市場准入計畫的必要組成部分。

供應商在專業零件領域的集中化，例如金屬夾的精密沖壓、客製化聚合物的擠出以及能量輸送系統的微電子元件，會造成策略依賴，進而影響定價和前置作業時間。因此，那些保持供應商多元化、投資於二級採購並實現關鍵能力內部化的公司，更有能力應對各種挑戰。能夠將臨床療效與可驗證的工作流程改進以及清晰的經濟效益相結合，從而引起醫院管理者和綜合醫療服務網路共鳴的機構，將日益獲得競爭優勢。

為加速推廣應用、降低供應鏈風險並增強臨床和商業性價值主張，可採取切實可行的策略性措施和營運措施。

產業領導者應採取一系列協調一致的策略行動，以解決產品設計、商業性准入和供應鏈韌性等問題。首先，應優先考慮模組化產品架構，以便進行增量升級並簡化監理申報流程。其次，應投入資源，收集將設備性能與臨床結果和營運指標連結起來的證據。現場試驗、註冊登記研究和手術全期工作流程研究將有助於醫院和門診中心更有力地論證採購理由。

第三，我們將考慮建立區域性製造地，以實現採購多元化並降低關稅和物流風險。第四，我們將透過類比、導師製網路和數位化學習平台，加強外科醫生培訓，以提升臨床醫生的信心，並縮短新設備和新手術流程的推廣應用週期。第五，我們將調整商業模式以適應終端用戶需求，並透過為門診中心提供捆綁式手術套件、為重症監護醫院提供專業支持方案，使價值主張與買方獎勵提案契合。

最後，要保持積極的監管溝通，並密切注意能量型和植入式組件相關標準的演變。儘早與監管和報銷利益相關人員接洽，可以加快產品進入市場，同時確保臨床數據收集能夠支持長期監測和經濟評估。這些措施共同構成了一個切實可行的藍圖，既兼顧了長期的臨床和商業性差異化優勢，也保證了短期營運的穩定性。

透過透明的混合方法研究框架獲得可靠的見解，該框架整合了臨床醫生訪談、監管機構審查、供應鏈圖譜和證據三角驗證。

本研究採用混合方法，將質性研究與定量二手資料結合，以多角度分析設備性能、推廣應用促進因素和供應鏈脆弱性。主要資料來源包括對心臟外科醫師、血管外科醫師、採購負責人、臨床營運負責人和生產主管的結構化訪談，並輔以手術室和設備訓練模擬的觀察資料。這些調查直接揭示了設備的易用性、部署挑戰和臨床醫生的偏好。

二次研究包括對同行評審的臨床文獻、監管文件、專利概況和技術白皮書進行系統性回顧，以檢驗性能聲明並追蹤創新軌跡。供應鏈映射結合了海關數據、供應商名錄和生產佈局分析，以識別集中風險和潛在的近岸外包機會。透過對多個資料來源的研究結果進行交叉檢驗、對情境假設進行敏感性測試以及由臨床和行業專家進行諮詢審查，確保了調查方法和資料來源的嚴謹性。

本研究遵循倫理原則，所有專有資料均嚴格保密。此綜合報告優先考慮可直接滿足採購、研發和商業規劃需求的實用訊息，確保檢驗均基於可觀察的趨勢和經實踐驗證的經驗，而非依賴未經證實的說法。

將臨床創新、營運韌性和商業策略連結起來的簡明綜合分析，有助於高階主管對醫療器材專案做出自信的決策。

最後，心血管吻合器材領域正朝著兼顧臨床療效和操作效率的解決方案發展。材料和能量輸送方面的創新，以及微創和機器人手術的普及，正在重新定義臨床醫生對器械的期望，同時也凸顯了互通性和循證價值提案的重要性。供應鏈壓力和不斷變化的貿易政策進一步強調了靈活籌資策略和敏捷生產的重要性。

決策者若能將產品開發與明確的流程需求結合，投資於嚴謹的臨床和經濟證據，並採用穩健的生產和採購慣例，將更有利於實現永續的市場推廣。同樣，重視終端使用者培訓、簡化設備介面並採取有針對性的地域策略的機構，將能夠加速在高潛力臨床領域的推廣應用。本文旨在為戰術性選擇和策略投資重點提供參考，從而推動改善患者預後並實現永續的商業性績效。

透過結合臨床考量、供應鏈實際情況和競爭格局，該分析可以幫助高階主管和臨床領導者就投資方向、如何降低風險以及如何在不同的醫療保健環境中擴大創新規模做出深思熟慮、充滿信心的決策。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合機器人輔助系統以提高冠狀動脈吻合術的精確度
  • 開發生物可吸收連接器以減少血管吻合術中的長期異物反應
  • 使用無縫線磁壓裝置加速冠狀動脈繞道手術（CABG）術後康復
  • 內視鏡吻合工具的進步使得透過較小的切口進行微創旁路移植手術成為可能。
  • 3D列印患者特異性吻合導板的出現，有助於最佳化移植物對位並減少手術誤差。
  • 整合感測器輔助吻合裝置，用於即時監測移植血管通暢性和血流動力學
  • 醫療科技公司與人工智慧供應商合作開發用於預測吻合器性能和結果的預測分析技術
  • 監管核准和報銷政策的改變促進了新型自動縫合器在心血管外科手術中的廣泛應用。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 心血管吻合器材市場（依產品類型分類）

  • 夾子
    • 止血夾
      • 金屬夾
      • 聚合物夾
    • 血管夾
  • 訂書機
    • 圓形訂書機
    • 直線型訂書機
      • 未加固
      • 加強
  • 縫合器械
    • 自動縫合
      • 手持式縫合器械
      • 機器人縫合裝置
    • 手工縫合

9. 心血管吻合裝置市場（依機制分類）

  • 膠水
    • 纖維蛋白膠
    • 合成密封劑
  • 夾鉗
  • 壓縮
    • 吻合環
    • 扣上
      • 生物可吸收扣
      • 金屬扣
  • 基於能源
    • 電暖型
    • 雷射
    • 超音波
  • 用訂書釘裝訂

第10章 心血管吻合器械市場（依手術類型分類）

  • 冠狀動脈繞道手術
    • 非泵送
    • 泵浦上
  • 周邊血管
    • 頸動脈
    • 股膕動脈
    • 腎
  • 閥門維修

第11章 心血管吻合器材市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

12. 心血管吻合器材市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 心血管吻合器材市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國心血管吻合器材市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medtronic plc
    • Abbott Laboratories
    • TERUMO Corporation
    • Johnson & Johnson
    • WL Gore & Associates, Inc.
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Teleflex Incorporated
    • Getinge AB
    • CryoLife, Inc.
Product Code: MRR-8C74ADFBF9A7

The Cardiovascular Anastomosis Devices Market is projected to grow by USD 4.55 billion at a CAGR of 11.00% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.97 billion
Estimated Year [2025] USD 2.19 billion
Forecast Year [2032] USD 4.55 billion
CAGR (%) 11.00%

A clear and authoritative orientation to the current device ecosystem, clinical considerations, and operational priorities shaping cardiovascular anastomosis today

Cardiovascular anastomosis devices sit at the intersection of surgical technique, materials science, and systems-level healthcare delivery. This introduction frames the contemporary landscape of tools used to establish and secure vascular and cardiac connections during a wide range of procedures, highlighting the ways that device form factors, mechanism of action, and clinical workflows interact to influence outcomes. The discipline has advanced from manual suturing toward mechanized, energy-assisted, and hybrid solutions designed to standardize reproducibility, reduce operative time, and mitigate complications.

Across the portfolio of devices discussed here, clinicians and healthcare organizations increasingly evaluate performance not only by ease of use but by durability, hemostasis efficiency, and compatibility with minimally invasive and robotic approaches. The integration of new polymers, metals, and energy delivery systems has expanded options for surgeons while adding complexity to procurement, training, and regulatory pathways. As stakeholders adopt novel approaches, the balance between device efficacy, clinician ergonomics, and total procedure cost becomes central to commercial conversations.

This introduction sets expectations for the following sections: an analysis of the tectonic shifts reshaping practice, a scenario-based view of tariff impacts, segmentation-driven insights that clarify product and clinical niches, and regional and competitive intelligence designed to inform practical strategy. The aim is to equip decision-makers with clear thematic takeaways that support immediate tactical choices and mid-term strategic planning.

How minimally invasive trends, materials breakthroughs, device interoperability, and evolving procurement models are redefining surgical anastomosis practices

Several transformative shifts are reshaping how cardiovascular anastomosis devices are designed, adopted, and commercialized, with implications that extend across clinical, manufacturing, and reimbursement domains. First, the steady move toward minimally invasive and robotic-assisted surgery has increased demand for devices that provide consistent, reproducible anastomoses within constrained access corridors; this trend is accelerating iterative refinements in form factor, articulation, and integration with robotic platforms. As a result, product development now emphasizes modular interfaces and compatibility standards that allow quicker clinical adoption and lower training burden.

Second, materials innovation-ranging from polymer formulations for absorbable components to new alloys and coatings for hemostatic clips-has expanded device longevity and biocompatibility while enabling engineers to reduce profile footprint and improve deployment reliability. Concurrently, energy-based technologies such as electrothermal and ultrasonic modalities are being refined to deliver controlled tissue effects, reducing bleeding and shortening operative time when properly matched to the clinical indication.

Third, procurement dynamics are evolving as ambulatory surgery centers gain greater procedural volume and hospitals pursue value-based metrics; this has heightened focus on total procedural cost, inventory optimization, and interoperability with existing devices. Lastly, regulatory and clinical-evidence expectations are rising, driving firms to invest in robust comparative studies and real-world evidence generation that demonstrate not only safety and efficacy but also downstream economic and workflow benefits. Taken together, these forces are producing a market environment where technical differentiation, clinical validation, and distribution agility determine the leaders in device adoption.

A practical analysis of how evolving US tariff dynamics drive supply chain reengineering, pricing pressure, and opportunities for local manufacturing resilience

The imposition and escalation of tariffs originating from policy shifts in major markets can materially influence supply chain choices, sourcing strategies, and component economics for manufacturers and distributors of cardiovascular anastomosis devices. When import levies are introduced or increased, firms that rely on cross-border sourcing for precision metal components, advanced polymers, electronic control units, or robotic subsystems must reassess supplier relationships and inventory practices to maintain margin and availability.

In practical terms, tariffs often catalyze near-term cost passthrough to buyers or compression of supplier margins, creating pressure to redesign devices for fewer tariff-sensitive inputs or to qualify local manufacturers who can supply key subassemblies. Manufacturers may pursue regional production hubs or toll-manufacturing agreements to mitigate exposure to targeted levies. At the same time, elevated import costs can accelerate vertical integration for components with high tariff risk, prompting manufacturers to acquire or partner with specialized suppliers to secure continuity and reduce unit cost volatility.

Clinically, procurement teams and hospital systems respond to tariff-driven price changes by tightening evaluation criteria, increasing competitive bidding, and prioritizing multi-use or reusable solutions where appropriate. Reimbursement administrators and value committees may demand clearer evidence of cost-benefit under new input-cost realities. For innovation-driven companies, tariffs create both challenges and opportunities: while they can increase near-term commercial friction, they also incentivize product simplification, localization of sensitive supply chains, and the development of incremental improvements that reduce reliance on imported materials and finished goods. Thus, tariff scenarios should be integrated into strategic planning as an ongoing supply-chain and pricing risk that requires coordinated responses across procurement, regulatory affairs, and product development.

A multi-dimensional segmentation synthesis that aligns product type, mechanism, procedure, and end-user parameters to reveal precise clinical and commercial target zones

Understanding product and clinical niches requires a layered segmentation approach that clarifies where innovation and commercialization can most effectively be targeted. By product type, the device universe encompasses clips, staplers, and suture devices. Clips are used for rapid vessel control and are typified by hemostatic clips and ligating clips; hemostatic clips themselves are delivered in metal and polymer variants that trade off permanence and imaging compatibility. Staplers include circular and linear configurations, and within linear staplers manufacturers distinguish between non-reinforced and reinforced variants to address tissue thickness and leak resistance. Suture devices span automated suturing and manual suturing techniques, with the automated category further divided into handheld suturators and robotic suturators that target different levels of automation and procedural complexity.

By mechanism of action, devices are organized across adhesive solutions, clamping systems, compression mechanisms, energy-based modalities, and stapling. Adhesive technologies include biologic fibrin sealants and synthetic sealants, each offering distinct handling and hemostatic profiles. Compression strategies cover anastomotic rings and buckles, and buckles may be bioabsorbable or metal depending on the intended permanence. Energy-based devices deploy electrothermal, laser, or ultrasonic effects to seal tissue and control bleeding while minimizing collateral thermal injury.

By procedure type, device selection aligns with the clinical context: coronary bypass surgery-performed off-pump or on-pump-creates one set of anastomotic challenges, whereas peripheral vascular procedures such as carotid, femoropopliteal, and renal interventions demand devices optimized for vessel size, accessibility, and plaque burden. Valve repair procedures introduce additional anatomical and hemodynamic constraints that influence device selection and deployment technique. Finally, end-user segmentation highlights the delivery environment: ambulatory surgery centers, hospitals, and specialty clinics each impose distinct requirements in terms of device footprint, sterilization workflows, and staff training. Appreciating these interlocking segmentation layers enables firms to tailor product design, clinical evidence generation, and commercialization pathways to the realities of distinct clinical and operational settings.

How regional clinical priorities, regulatory environments, and supply chain footprints differentially influence device adoption across Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption pathways, regulatory hurdles, and supply-chain design in ways that affect strategy and execution. In the Americas, clinical emphasis on minimally invasive coronary and peripheral interventions intersects with a mature reimbursement infrastructure and sophisticated hospital purchasing processes. Providers in major markets prioritize devices that demonstrably reduce operating time, lower complication rates, and integrate with existing surgical platforms. Meanwhile, regional manufacturers and contract manufacturers play a significant role in providing localized supply and rapid replenishment, which benefits high-volume centers.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory alignment across countries and strong national procurement agencies can accelerate adoption when evidence is compelling, but fragmentation across markets requires tailored regulatory and reimbursement strategies. Several European markets have high expectations for real-world evidence and cost-effectiveness data, and procurement bodies often demand long-term safety information for devices intended to be permanent or semi-permanent.

Asia-Pacific is characterized by rapid growth in procedural volumes, expanding investment in hospital infrastructure, and a dual market structure that includes both high-end tertiary care centers and resource-constrained facilities. Local OEMs and regional supply chains are increasingly sophisticated, and multinational vendors often pursue partnerships or local production to meet regulatory and cost requirements. Across regions, companies that align product portfolios to local procedural patterns, regulatory timing, and purchasing models gain the clearest path to sustained adoption.

An incisive review of competitive positioning, partnership dynamics, supplier concentration, and the innovation pathways shaping device leadership

Competitive dynamics in cardiovascular anastomosis devices are shaped by a mix of incumbent medical-device firms, specialized mid-sized innovators, and a growing cohort of technology-focused startups. Established manufacturers leverage broad commercial channels, regulatory experience, and existing clinical relationships to scale distribution quickly, while smaller players advance disruptive features-such as advanced energy control algorithms, novel absorbable polymers, or compact robotic suturing modules-that attract early-adopter surgeons and strategic acquirers.

Partnerships and co-development agreements between device companies and robotic platform providers have intensified as both sides seek to ensure interoperability and bundled clinical value propositions. Cross-disciplinary collaboration between materials scientists, clinical researchers, and systems engineers has produced a pipeline of incremental innovations that improve handling, reduce device profile, and enhance hemostasis. At the same time, regulatory pathways emphasizing clinical evidence and post-market surveillance have raised the bar for new entrants, making clinical trial design, registry participation, and formal health-economics analysis essential components of go-to-market plans.

Supplier concentration for specialized components-precision stamping for metal clips, custom polymer extrusion, and microelectronics for energy delivery systems-creates strategic dependencies that influence pricing and lead times. Consequently, firms that maintain diversified supplier bases, invest in secondary sourcing, or internalize key capabilities are better positioned to manage disruption. Competitive advantage increasingly accrues to organizations that can pair clinical efficacy with demonstrable workflow improvements and clear economic narratives that resonate with hospital administrators and integrated delivery networks.

Practical strategic moves and operational measures to accelerate adoption, de-risk supply chains, and strengthen clinical and commercial value propositions

Industry leaders should adopt a coordinated set of strategic actions that address product design, commercial access, and supply-chain resilience. First, prioritize modular product architectures that enable incremental upgrades and simplified regulatory submissions; this reduces time-to-adoption and allows manufacturers to introduce targeted improvements without broad redesign. Second, invest in evidence generation that links device performance to clinical outcomes and operational metrics; pragmatic trials, registry participation, and perioperative workflow studies will strengthen purchasing cases in both hospitals and ambulatory centers.

Third, diversify sourcing and consider regional manufacturing footprints to mitigate tariff exposure and logistics risk; dual-sourcing agreements, qualified contract manufacturers in strategic geographies, and selective vertical integration for high-risk components will reduce vulnerability to trade disruptions. Fourth, enhance surgeon training pathways through simulation, proctoring networks, and digital learning platforms to accelerate clinician confidence and shorten the adoption curve for new devices or techniques. Fifth, tailor commercial models to end-user needs by offering bundled procedural kits for ambulatory centers and specialized support packages for high-acuity hospitals, thereby aligning value propositions with purchaser incentives.

Finally, maintain an active regulatory engagement plan and monitor evolving standards for energy-based and implantable components. Engaging early with regulators and reimbursement stakeholders can expedite market access while ensuring that clinical data collection supports long-term surveillance and economic assessment. Together, these actions form a pragmatic roadmap that balances near-term operational resilience with long-term clinical and commercial differentiation.

A transparent mixed-methods research framework integrating clinician interviews, regulatory review, supply-chain mapping, and evidence triangulation to ensure robust insights

The research applied a mixed-methods approach that triangulated primary qualitative engagement with quantitative secondary data to build a multi-perspective view of device performance, adoption drivers, and supply-chain vulnerabilities. Primary inputs included structured interviews with cardiac and vascular surgeons, procurement officers, clinical affairs leaders, and manufacturing executives, supplemented by observational inputs from procedure rooms and device training simulations. These engagements provided first-hand insights into device usability, deployment challenges, and clinician preferences.

Secondary research encompassed systematic reviews of peer-reviewed clinical literature, regulatory filings, patent landscapes, and technology white papers to validate performance claims and trace innovation trajectories. Supply-chain mapping combined customs data, supplier directories, and manufacturing footprint analysis to identify concentration risks and potential nearshoring opportunities. Methodological rigor was ensured through cross-validation of findings across multiple data sources, sensitivity testing of scenario assumptions, and advisory review by clinical and industry experts.

Ethical research practices were observed throughout, and proprietary data were handled under strict confidentiality protocols. The synthesis prioritized actionable intelligence that speaks directly to procurement, R&D, and commercial planning needs without relying on unverifiable claims, ensuring that recommendations are grounded in observable trends and corroborated practitioner experience.

A concise synthesis linking clinical innovation, operational resilience, and commercial strategy to inform confident executive decision-making in device programs

In closing, the cardiovascular anastomosis device landscape is transitioning toward solutions that harmonize clinical efficacy with operational efficiency. Innovations in materials and energy delivery, along with the spread of minimally invasive and robotic approaches, are redefining what clinicians expect from devices while amplifying the importance of interoperability and evidence-based value propositions. Supply-chain pressures and trade-policy shifts further underscore the need for flexible sourcing strategies and manufacturing agility.

Decision-makers who align product development with clear procedural needs, invest in rigorous clinical and economic evidence, and adopt resilient manufacturing and procurement practices will be best positioned to capture sustainable adoption. Equally, organizations that prioritize end-user training, simplified device interfaces, and targeted regional strategies can accelerate uptake in high-opportunity clinical segments. The synthesis presented here is intended to inform tactical choices and strategic investment priorities that drive both improved patient outcomes and durable commercial performance.

By bringing clinical insight, supply-chain realism, and competitive clarity together, this analysis supports executives and clinical leaders in making measured, high-confidence decisions about where to invest, how to mitigate risk, and how to scale innovations across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of robotic-assisted systems to enhance precision in coronary anastomosis procedures
  • 5.2. Development of bioabsorbable couplers for reducing long-term foreign body response in vessel anastomosis
  • 5.3. Adoption of sutureless magnetic compression devices to accelerate postoperative recovery in CABG surgeries
  • 5.4. Advancements in endoscopic anastomosis tools facilitating minimally invasive bypass graft procedures with smaller incisions
  • 5.5. Emergence of 3D-printed patient-specific anastomotic guides to optimize graft alignment and reduce surgical errors
  • 5.6. Integration of sensor-enabled anastomosis devices for real-time monitoring of graft patency and blood flow dynamics
  • 5.7. Collaborations between medtech firms and AI vendors to develop predictive analytics for anastomosis device performance and outcomes
  • 5.8. Regulatory approvals and reimbursement shifts driving uptake of novel automated stapling devices in cardiovascular surgery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Anastomosis Devices Market, by Product Type

  • 8.1. Clips
    • 8.1.1. Hemostatic Clips
      • 8.1.1.1. Metal Clips
      • 8.1.1.2. Polymer Clips
    • 8.1.2. Ligating Clips
  • 8.2. Staplers
    • 8.2.1. Circular Staplers
    • 8.2.2. Linear Staplers
      • 8.2.2.1. Non Reinforced
      • 8.2.2.2. Reinforced
  • 8.3. Suture Devices
    • 8.3.1. Automated Suturing
      • 8.3.1.1. Handheld Suturer
      • 8.3.1.2. Robotic Suturer
    • 8.3.2. Manual Suturing

9. Cardiovascular Anastomosis Devices Market, by Mechanism

  • 9.1. Adhesive
    • 9.1.1. Fibrin Sealants
    • 9.1.2. Synthetic Sealants
  • 9.2. Clamping
  • 9.3. Compression
    • 9.3.1. Anastomotic Rings
    • 9.3.2. Buckles
      • 9.3.2.1. Bioabsorbable Buckles
      • 9.3.2.2. Metal Buckles
  • 9.4. Energy Based
    • 9.4.1. Electrothermal
    • 9.4.2. Laser
    • 9.4.3. Ultrasonic
  • 9.5. Stapling

10. Cardiovascular Anastomosis Devices Market, by Procedure Type

  • 10.1. Coronary Bypass
    • 10.1.1. Off Pump
    • 10.1.2. On Pump
  • 10.2. Peripheral Vascular
    • 10.2.1. Carotid
    • 10.2.2. Femoropopliteal
    • 10.2.3. Renal
  • 10.3. Valve Repair

11. Cardiovascular Anastomosis Devices Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Cardiovascular Anastomosis Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiovascular Anastomosis Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiovascular Anastomosis Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Abbott Laboratories
    • 15.3.3. TERUMO Corporation
    • 15.3.4. Johnson & Johnson
    • 15.3.5. W. L. Gore & Associates, Inc.
    • 15.3.6. Baxter International Inc.
    • 15.3.7. B. Braun Melsungen AG
    • 15.3.8. Teleflex Incorporated
    • 15.3.9. Getinge AB
    • 15.3.10. CryoLife, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERIC